UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Some remaining challenges regarding multiple endpoints in clinical trials

Statistics in medicine, 2017-12, Vol.36 (28), p.4441-4445

Snapinn, Steven

2017

Volltextzugriff (PDF)

Responder analyses and the assessment of a clinically relevant treatment effect

Trials, 2007-10, Vol.8 (1), p.31-31, Article 31

2007

Volltextzugriff (PDF)

A shrinkage estimator for subgroup analysis without the exchangeability assumption

Journal of biopharmaceutical statistics, 2021-11, Vol.31 (6), p.723-735

Snapinn, Steven

2021

Volltextzugriff (PDF)

Illustrating the Impact of a Time-Varying Covariate With an Extended Kaplan-Meier Estimator

The American statistician, 2005-11, Vol.59 (4), p.301-307

2005

Volltextzugriff (PDF)

Noninferiority trials

Trials, 2000-07, Vol.1 (1), Article 19

Snapinn, Steven M

2000

Volltextzugriff (PDF)

University of Pennsylvania 10th annual conference on statistical issues in clinical trials: Current issues regarding data and safety monitoring committees in clinical trials (morning panel session)

Clinical trials (London, England), 2018-08, Vol.15 (4), p.335-351

2018

Volltextzugriff (PDF)

Does Albuminuria Predict Cardiovascular Outcomes on Treatment With Losartan Versus Atenolol in Patients With Diabetes, Hypertension, and Left Ventricular Hypertrophy?: The LIFE study

Diabetes care, 2006-03, Vol.29 (3), p.595-600

2006

Volltextzugriff (PDF)

Alternatives for Discounting in the Analysis of Noninferiority Trials

Journal of biopharmaceutical statistics, 2004-12, Vol.14 (2), p.263-273

Snapinn, Steven M.

2004

Volltextzugriff (PDF)

Hospitalizations for New Heart Failure Among Subjects With Diabetes Mellitus in the RENAAL and LIFE Studies

The American journal of cardiology, 2005-12, Vol.96 (11), p.1530-1536

2005

Volltextzugriff (PDF)

Stroke Reduction in Hypertensive Adults With Cardiac Hypertrophy Randomized to Losartan Versus Atenolol: The Losartan Intervention For Endpoint Reduction in Hypertension Study

Hypertension (Dallas, Tex. 1979), 2005-01, Vol.45 (1), p.46-52

2005

Volltextzugriff (PDF)

Treatment effect measures under nonproportional hazards

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2023-01, Vol.22 (1), p.181-193

2023

Volltextzugriff (PDF)

The issue of multiplicity in noninferiority studies

Clinical trials (London, England), 2012-12, Vol.9 (6), p.730-735

2012

Volltextzugriff (PDF)

Preservation of effect and the regulatory approval of new treatments on the basis of non-inferiority trials

Statistics in medicine, 2008-02, Vol.27 (3), p.382-391

2008

Volltextzugriff (PDF)

Controlling the type 1 error rate in non-inferiority trials

Statistics in medicine, 2008-02, Vol.27 (3), p.371-381

2008

Volltextzugriff (PDF)

Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease

The New England journal of medicine, 2022-12, Vol.387 (26), p.2481-2485

2022

Volltextzugriff (PDF)

Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial

The American journal of cardiology, 2004-04, Vol.93 (7), p.843-847

2004

Volltextzugriff (PDF)

Informative noncompliance in endpoint trials

Current controlled trials in cardiovascular medicine, 2004-07, Vol.5 (1), Article 5

2004

Volltextzugriff (PDF)

Survival Analysis with Uncertain Endpoints

Biometrics, 1998-03, Vol.54 (1), p.209-218

Snapinn, Steven M.

1998

Volltextzugriff (PDF)

Predicting analysis time in event-driven clinical trials with event-reporting lag

Statistics in medicine, 2012-04, Vol.31 (9), p.801-811

2012

Volltextzugriff (PDF)

Incorporation of Clinical Meaningfulness Into the Analysis of a Continuous Variable: A More Powerful Alternative to the Responder Analysis

Statistics in biopharmaceutical research, 2014-10, Vol.6 (4), p.349-355

2014

Volltextzugriff (PDF)

Statistical Considerations on the Evaluation of Imbalances of Adverse Events in Randomized Clinical Trials

Therapeutic innovation & regulatory science, 2015-11, Vol.49 (6), p.957-965

2015

Volltextzugriff (PDF)

Choosing Appropriate Metrics to Evaluate Adverse Events in Safety Evaluation

Therapeutic innovation & regulatory science, 2015-05, Vol.49 (3), p.398-404

2015

Volltextzugriff (PDF)

Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study

The Lancet (British edition), 2003-08, Vol.362 (9384), p.619-620

2003

Volltextzugriff (PDF)

Responsibilities of Data Monitoring Committees: Consensus Recommendations

Therapeutic innovation & regulatory science, 2016-09, Vol.50 (5), p.648-659

2016

Volltextzugriff (PDF)

Calculation of Sample Size in Survival Trials: The Impact of Informative Noncompliance

Biometrics, 2004-09, Vol.60 (3), p.800-806

2004

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Aktive Filter

ThemaClinical Trials

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(28)

Sprache

Englisch
(28)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Some remaining challenges regarding multiple endpoints in clinical trials

Responder analyses and the assessment of a clinically relevant treatment effect

A shrinkage estimator for subgroup analysis without the exchangeability assumption

Illustrating the Impact of a Time-Varying Covariate With an Extended Kaplan-Meier Estimator

Noninferiority trials

University of Pennsylvania 10th annual conference on statistical issues in clinical trials: Current issues regarding data and safety monitoring committees in clinical trials (morning panel session)

Does Albuminuria Predict Cardiovascular Outcomes on Treatment With Losartan Versus Atenolol in Patients With Diabetes, Hypertension, and Left Ventricular Hypertrophy?: The LIFE study

Alternatives for Discounting in the Analysis of Noninferiority Trials

Hospitalizations for New Heart Failure Among Subjects With Diabetes Mellitus in the RENAAL and LIFE Studies

Stroke Reduction in Hypertensive Adults With Cardiac Hypertrophy Randomized to Losartan Versus Atenolol: The Losartan Intervention For Endpoint Reduction in Hypertension Study

Treatment effect measures under nonproportional hazards

The issue of multiplicity in noninferiority studies

Preservation of effect and the regulatory approval of new treatments on the basis of non-inferiority trials

Controlling the type 1 error rate in non-inferiority trials

Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease

Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial

Informative noncompliance in endpoint trials

Survival Analysis with Uncertain Endpoints

Predicting analysis time in event-driven clinical trials with event-reporting lag

Incorporation of Clinical Meaningfulness Into the Analysis of a Continuous Variable: A More Powerful Alternative to the Responder Analysis

Statistical Considerations on the Evaluation of Imbalances of Adverse Events in Randomized Clinical Trials

Choosing Appropriate Metrics to Evaluate Adverse Events in Safety Evaluation

Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study

Responsibilities of Data Monitoring Committees: Consensus Recommendations

Calculation of Sample Size in Survival Trials: The Impact of Informative Noncompliance

Aktive Filter

Suchergebnisse filtern